KRAS and familial pancreatic carcinoma: It has shown good efficacy and tolerability in phase 1 trials (https://clinicaltrials.gov/ct2/show/NCT01188785 accessed on 10 May 2021), and it is currently under clinical evaluation in a phase 2 trial to assess the response rate when it is combined with chemotherapy treatment in pancreatic cancer patients with KRAS mutations (https://clinicaltrials.gov/ct2/show/NCT01676259 accessed on 10 May 2021).